• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical hypertension. >The New Anticoagulant Drugs: Are They Really Superior to Warfarin?
【24h】

The New Anticoagulant Drugs: Are They Really Superior to Warfarin?

机译：新的抗凝药物：它们真的优于华法林吗？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Three large trials (ie, the Randomized Evaluation of Long-Term Anticoagulation Therapy [RE-LY], the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation [ROCKET-AF], and the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation [ARISTOTLE] trials)1"3 were recently published to test the efficacy and safety of new oral anticoagulants in preventing stroke and systemic embolism in patients with nonvalvular atrial fibrillation. The three studies, despite their important differences in design and clinical profile of the participants, consistently demonstrated at least noninferiority for both efficacy and safety for the newer anticoagulants (ie, dabigatran, rivaroxaban, apixaban) vs warfarin. Beyond the already emerged debate relative to the clinical application of the newer agents,4'5 there are further obscured points seeking clear answers in order to better evaluate whether there is a clinically relevant link between implemented randomized treatments and investigated outcome.
机译：三项大型试验（即长期抗凝治疗的随机评估[RE-LY]，利伐沙班每日一次口服直接因子Xa抑制与维生素K拮抗作用相比较预防心房纤颤的卒中和栓塞试验[ROCKET-AF] ，最近还发表了Apixaban减少房颤中风和其他血栓栓塞事件的研究[ARISTOTLE] 1“ 3，以测试新型口服抗凝剂在预防非瓣膜性房颤患者中风和全身性栓塞中的有效性和安全性。三项研究尽管参与者的设计和临床特征存在重大差异，但始终证明至少较新的抗凝剂（即达比加群，利伐沙班，阿哌沙班）与华法林在疗效和安全性方面均不逊色。新药的临床应用[4,5]，还有进一步的模糊点，寻求明确答案才能下注评估实施的随机治疗与研究结果之间是否存在临床相关的联系。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号